Life sciences software & AI news

Daily news on AI, software, and digital tools for pharma, biotech, CROs, and life sciences research labs.

Showing 1000+ results
An ultrasound transducer on a patient's abdomen in a dimly lit clinical room.

Jun 14, 2026

United States Ultrasound Device Market Outlook 2026–2034: How AI, Portability, and Point-of-Care Imaging Are Transforming Diagnostics

The ultrasound device market in the United States is poised for significant growth, driven by technological advancements, particularly in AI and portable imaging systems.Ultrasound technology stands out in medical imaging due to its non-invasive nature and safety, utilizing sound waves to create real-time images without radiation exposure. This versatility makes it crucial across various medical fields, including cardiology and obstetrics. The market is projected to expand from $2.73 billion in
Telemedicine device in a clinical setting

Jun 14, 2026

National Centre for Digital Health established to drive telemedicine, AI and health innovation

A new institution, the Pakistan Center for Digital Health (PCDH), has been established to enhance digital health, telemedicine, and AI integration in Pakistan's healthcare system. This initiative, backed by the Ministry of National Health Services, aims to improve healthcare delivery, especially in underserved areas.The PCDH was formed through a memorandum of understanding between Digital Health Pakistan and the Health Services Academy, with key health officials in attendance. This center is a r
A minimalist representation of a drug capsule and KRAS protein structure.

Jun 14, 2026

How Astellas’ AI-Driven Clinical Overhaul and KRAS Bet Will Impact Astellas Pharma (TSE:4503) Investors

Astellas Pharma is transforming its drug development strategy by integrating AI tools and bringing clinical operations in-house, particularly as it advances its KRAS-targeting candidate, setidegrasib, into a phase 3 trial for pancreatic cancer. This strategic pivot aims to enhance research and development efficiency, positioning the company to compete in the crowded oncology landscape while also exploring opportunities in gene therapy and targeted protein degradation.Astellas' shift to AI-driven
Minimalist illustration of a GPCR and small molecule drug

Jun 14, 2026

XtalPi Biopharma GPCR Pact Tests AI Drug Discovery And Revenue Potential

XtalPi Holdings has announced a significant partnership with a global biopharma firm aimed at developing oral small molecule drugs that target complex G protein-coupled receptors (GPCRs). This collaboration leverages XtalPi's advanced AI and quantum physics platforms, alongside automated laboratories, to address challenges in GPCR drug discovery.The partnership is valued at over $400 million, indicating a substantial commercial opportunity for XtalPi's innovative technology. Despite recent fluct
A minimalist illustration of a money bag representing biotech investment.

Jun 13, 2026

Kos Biotechnology Partners Announces Third Closing of Global Life Sciences Fund at $123 Million

Kos Biotechnology Partners has successfully closed its inaugural global life sciences fund, amassing $123 million in capital commitments, marking a significant milestone in Greece's venture capital landscape.The firm, which connects the US biopharma ecosystem with Europe, has garnered support from notable institutional investors, including the Hellenic Development Bank of Investments. This fund represents a historic launch as the first dedicated life sciences investment fund in Greece and stands
A tissue sample on a microscope slide in a laboratory setting.

Jun 13, 2026

Astellas Pharma (TSE:4503) Stock Valuation After KRAS Trial Progress And AI Overhaul

Astellas Pharma is gaining investor attention due to its recent internal restructuring and advancements in clinical trials, particularly with its KRAS-targeting therapy setidegrasib, now in phase 3 for pancreatic cancer.Despite a recent decline in share price—down 10% over the last month and 9% over the last three months—Astellas has maintained a robust one-year total shareholder return of 60%. This suggests that while the stock's recent performance is being scrutinized, the overall market senti
A minimalist illustration of a stethoscope and AI symbol representing healthcare technology.

Jun 13, 2026

The digital health vacuum: Why Ghana’s legal frameworks are unprepared for medical AI -Michael Mensah writes

The integration of AI into Ghana's healthcare system raises critical legal and ethical questions regarding accountability and data protection, as highlighted by Valentine Golden Ghanem's insights.In Ghana, the rapid adoption of AI-assisted diagnostic tools in healthcare presents a pressing issue: the lack of clear legal accountability when these technologies fail. As AI systems become more prevalent, the question of liability remains unresolved, particularly when misdiagnoses occur due to algori
A circuit board and robotic arm in a workshop setting

Jun 13, 2026

Vector Institute Executive Urges Japan-Canada AI Collaboration

Cameron Schuler, a key figure at the Vector Institute, emphasizes the importance of AI collaboration between Japan and Canada.In a recent discussion with Jiji Press, Cameron Schuler highlighted the transformative potential of artificial intelligence, particularly in sectors such as manufacturing, financial services, and life sciences. He advocates for enhanced partnerships between Japanese and Canadian businesses to leverage AI's capabilities for future advancements. The Vector Institute, founde
A minimalist illustration of an ECG waveform and DNA helix on a solid background.

Jun 13, 2026

New FDA Clearances for Genomics and Cardiac AI Could Be A Game Changer For Tempus AI (TEM)

Tempus AI has recently achieved significant FDA approvals that could enhance its position in the precision medicine landscape. The company received clearance for its xT CDx sequencing platform focused on tumor-only indications and published a validation study for its ECG-AF software, which predicts the risk of atrial fibrillation or flutter over the next year.These developments highlight Tempus AI's strategy to integrate extensive genomic data with AI technologies, aiming to improve decision-mak
A blood pressure monitor in a clinical setting with a patient's arm

Jun 13, 2026

WHO SEARO and George Institute for Global Health lay focus on digital health and AI for NCDs

The WHO South-East Asia Regional Office (SEARO) has partnered with The George Institute for Global Health, India, to leverage digital health and artificial intelligence (AI) in addressing the rising prevalence of non-communicable diseases (NCDs) in the region.This collaboration, formalized through a Project Collaboration Agreement, is set to last for two years, starting from April 1, 2026. The initiative aims to enhance the design, implementation, evaluation, and scaling of evidence-based digita
A flat illustration of a fundus camera and an eye, symbolizing diabetic retinopathy screening.

Jun 13, 2026

Andhra Pradesh Launches AI Pilot for Diabetic Retinopathy Screening in Gov Hospitals

The government of Andhra Pradesh has initiated a pilot program utilizing Artificial Intelligence (AI) for the early detection of diabetic retinopathy in government hospitals.This innovative project, announced by Health Minister Y Satya Kumar Yadav, is being rolled out in hospitals located in Guntur, Kurnool, and Visakhapatnam. The AI system will analyze fundus camera images to determine the severity of diabetic retinopathy, which affects around 20% of individuals with diabetes. This condition ca
A clipboard with safety reports in a clinical office setting.

Jun 13, 2026

UCB Transforms Safety Operations with Veeva Safety Suite in Collaboration with ELIQUENT Life Sciences, Pinnaxis, and Daelight Solutions

UCB has successfully implemented the Veeva Safety Suite, marking a significant advancement in its global safety operations through a collaboration with ELIQUENT Life Sciences, Pinnaxis, and Daelight Solutions.The Veeva Safety Suite, which includes tools like Veeva Safety, SafetyDocs, Safety Signal, and Safety Workbench, offers a comprehensive solution for pharmacovigilance. This transition to a unified, cloud-based platform enhances UCB's case processing, signal detection, and reporting capabili